Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Zotepine in the treatment of acute hospitalized schizophrenic episodes
Autore:
Kasper, S; Quiner, S; Barnas, C; Fabisch, T; Haushofer, M; Sackel, C; Konig, P; Lingg, A; Platz, T; Rittmannsberger, H; Stuppack, C; Willeit, M; Zapotoczky, HG;
Indirizzi:
Univ Klin Psychiat, Klin Abt Allgemeine Psychiat, Vienna, Austria Univ Klin Psychiat Vienna Austria Allgemeine Psychiat, Vienna, Austria Univ Klin Psychiat, Graz, Austria Univ Klin Psychiat Graz AustriaUniv Klin Psychiat, Graz, Austria Donauspital, Sozialmed Zentrum Ost Stadt Wien, Psychiat Abt, Vienna, Austria Donauspital Vienna Austria st Stadt Wien, Psychiat Abt, Vienna, Austria Landesnervenklin Salzburg, Psychiat Abt 1, Salzburg, Austria Landesnervenklin Salzburg Salzburg Austria iat Abt 1, Salzburg, Austria Landeskrankenhaus Rankweil, Abt Psychiat & Neurol, Rankweil, Austria Landeskrankenhaus Rankweil Rankweil Austria & Neurol, Rankweil, Austria Landeskrankenhaus Klagenfurt, Zentrum Seel Gesundheit, Klagenfurt, AustriaLandeskrankenhaus Klagenfurt Klagenfurt Austria it, Klagenfurt, Austria Landesnervenklin Wagner Jauregg, Linz, Austria Landesnervenklin Wagner Jauregg Linz Austria ner Jauregg, Linz, Austria
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 3, volume: 16, anno: 2001,
pagine: 163 - 168
SICI:
0268-1315(200105)16:3<163:ZITTOA>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND TRIAL; NEGATIVE SYMPTOMS; HALOPERIDOL; SCALE;
Keywords:
antipsychotics; atypical antipsychotics; post-marketing surveillance study; schizophrenia; zotepine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Kasper, S Univ Vienna, Dept Gen Psychiat, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 ustria
Citazione:
S. Kasper et al., "Zotepine in the treatment of acute hospitalized schizophrenic episodes", INT CLIN PS, 16(3), 2001, pp. 163-168

Abstract

The atypical antipsychotic zotepine was studied in an open, multicentre uncontrolled, post-marketing surveillance study in 108 schizophrenic patientshospitalized in 12 trial centres in Austria. Within the dosage range of 50-450 mg (mean at the end of the study, 207 +/- 125 mg/day), a significant reduction of positive as well as negative symptoms was noted. There was no increase in extrapyramidal side-effects during the study and a significant decrease in akathisia scores. The medication was well tolerated during the 42-day observation period. Zotepine improved both positive and negative symptoms and was not accompanied by extrapyramidal side-effects, justifying itsclassification as an atypical antipsychotic. Int clin Psychopharmacol 16:163-168 (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 14:04:33